Evidence map›Paper›PMID 34269914›Full record

ReviewCurrent cardiology reports2021

Transcatheter Repair and Replacement Technologies for Mitral Regurgitation: a European Perspective.

Joris F Ooms, Nicolas M Van Mieghem

Abstract readReview
In one paragraph

Review in Current cardiology reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Impact and limitations of 3D computational modelling in transcatheter mitral valve replacement-a two-centre Dutch experience.Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation · 2024
    Article
  3. Cardiac intensive care unit: where we are in 2023.Frontiers in cardiovascular medicine · 2023
    Review
  4. Transcatheter Mitral Valve Repair with MitraClipHeart views : the official journal of the Gulf Heart Association
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Joris F OomsDepartment of Interventional Cardiology, Thoraxcenter, Erasmus University Medical Center, Office Nt 645, Dr. Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands.
Nicolas M Van MieghemDepartment of Interventional Cardiology, Thoraxcenter, Erasmus University Medical Center, Office Nt 645, Dr. Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands. n.vanmieghem@erasmusmc.nl.ORCID http://orcid.org/0000-0002-2732-1205

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewWe aimed to picture the contemporary landscape of available catheter-based repair and replacement solutions for mitral regurgitation (MR) in Europe. RECENT

findingsEdge-to-edge repair remains the dominant technique for transcatheter mitral valve repair especially in the context of secondary mitral regurgitation. Two recent randomized trials reported seemingly contradicting clinical results with transcatheter edge-to-edge repair for patients with heart failure and severe secondary MR. A proportionality framework related to secondary MR was proposed to help explain inconsistencies but requires further research. (In)Direct annuloplasty primarily aims to correct secondary MR; however, the scientific basis seems less robust. One dedicated transcatheter heart valve has the CE mark for mitral valve replacement but requires transapical access. Balloon-expandable transcatheter aortic valve platforms are emerging for transvenous transseptal mitral replacement in the context of mitral annular calcification, a failing surgical mitral bioprosthesis, or annuloplasty. Advanced computed tomography imaging techniques improved pre-procedural planning and introduced the option for modeling and simulation. Development of a toolbox of catheter-based technologies, complementary imaging modalities, and refined patient selection offer novel perspectives to high-risk patients with primary or secondary MR. Clinical trials are required to help formulate evidence-based guidelines for the management of mitral valve disease.

Indexed as

Heart Valve Prosthesis ImplantationMitral Valve AnnuloplastyMitral Valve InsufficiencyCardiac CatheterizationEuropeHumansMitral ValveTreatment OutcomeAdvanced pre-procedural planningAnnuloplastyEdge-to-edge coaptationMitral valve regurgitationPercutaneous repairTranscatheter replacement

Identifiers

PMID34269914
PMCPMC8285321

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.